300723 一品红
已收盘 08-07 15:00:00
资讯
新帖
简况
股市必读:一品红(300723)8月5日董秘有最新回复
证券之星 · 08-06 01:19
股市必读:一品红(300723)8月5日董秘有最新回复
一品红(300723)7月31日股东户数3.28万户,较上期减少0.75%
证券之星 · 08-04 17:52
一品红(300723)7月31日股东户数3.28万户,较上期减少0.75%
一品红:2025年11月AR882国内Ⅲ期临床试验完成全部患者入组
证券之星 · 08-04 16:21
一品红:2025年11月AR882国内Ⅲ期临床试验完成全部患者入组
一品红:截止至2026年7月31日,公司股东总户数32,828户
证券之星 · 08-04 16:21
一品红:截止至2026年7月31日,公司股东总户数32,828户
一品红(300723)7月31日股东户数3.28万户,较上期减少0.75%
证券之星 · 08-03
一品红(300723)7月31日股东户数3.28万户,较上期减少0.75%
一品红:截止至2026年7月31日,公司股东总户数32,828户
证券之星 · 08-03
一品红:截止至2026年7月31日,公司股东总户数32,828户
一品红最新公告:全资子公司拟中标348.17万元药品项目
证券之星 · 08-03
一品红最新公告:全资子公司拟中标348.17万元药品项目
一品红(300723)披露2026年第二次临时股东会决议公告,7月24日股价下跌4.73%
证券之星 · 07-24
一品红(300723)披露2026年第二次临时股东会决议公告,7月24日股价下跌4.73%
一品红(300723)披露2025年股票期权激励计划部分股票期权注销完成公告,7月23日股价下跌1.31%
证券之星 · 07-23
一品红(300723)披露2025年股票期权激励计划部分股票期权注销完成公告,7月23日股价下跌1.31%
一品红(300723.SZ)子公司获得苯溴马隆片注册证书
智通财经 · 07-23
一品红(300723.SZ)子公司获得苯溴马隆片注册证书
一品红(300723)披露2025年股票期权激励计划第一个行权期采用自主行权安排,7月17日股价下跌12.38%
证券之星 · 07-17
一品红(300723)披露2025年股票期权激励计划第一个行权期采用自主行权安排,7月17日股价下跌12.38%
7月17日一品红跌12.38%,新华鑫益灵活配置混合A基金重仓该股
证券之星 · 07-17
7月17日一品红跌12.38%,新华鑫益灵活配置混合A基金重仓该股
股市必读:一品红(300723)7月14日董秘有最新回复
证券之星 · 07-15
股市必读:一品红(300723)7月14日董秘有最新回复
一品红:2025年11月AR882国内Ⅲ期临床试验完成全部患者入组
证券之星 · 07-14
一品红:2025年11月AR882国内Ⅲ期临床试验完成全部患者入组
一品红(300723)披露2025年股票期权激励计划第一个行权期行权条件成就公告,7月13日股价下跌0.98%
证券之星 · 07-13
一品红(300723)披露2025年股票期权激励计划第一个行权期行权条件成就公告,7月13日股价下跌0.98%
一品红(300723)披露召开2026年第二次临时股东大会通知,7月8日股价下跌2.36%
证券之星 · 07-08
一品红(300723)披露召开2026年第二次临时股东大会通知,7月8日股价下跌2.36%
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
证券之星 · 07-06
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
一品红:截止至2026年6月30日,公司股东总户数33,076户
证券之星 · 07-06
一品红:截止至2026年6月30日,公司股东总户数33,076户
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
证券之星 · 07-02
一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%
一品红:截止至2026年6月30日,公司股东总户数33,076户
证券之星 · 07-02
一品红:截止至2026年6月30日,公司股东总户数33,076户
加载更多
公司概况
公司名称:
一品红药业集团股份有限公司
所属行业:
医药制造业
上市日期:
2017-11-16
主营业务:
一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系,结合多年的市场经验,公司形成了覆盖面广、重点突出、阶梯化储备的产品结构,聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日,公司(含全资及控股子公司)新增技术发明专利5项,目前,公司共有专利125项,其中国内专利114项,境外专利11项;共有商标477项,软件著作权45项。
发行价格:
17.05
{"stockData":{"symbol":"300723","market":"SZ","secType":"STK","nameCN":"一品红","latestPrice":37.99,"timestamp":1786086216000,"preClose":36.46,"halted":0,"volume":16250319,"delay":0,"changeRate":0.042,"floatShares":419000000,"shares":451999999,"eps":0.4428,"marketStatus":"已收盘","change":1.53,"latestTime":"08-07 15:00:00","open":36.08,"high":38.38,"low":35.83,"amount":607000000,"amplitude":0.0699,"askPrice":38,"askSize":192,"bidPrice":37.99,"bidSize":916,"shortable":0,"etf":0,"ttmEps":0.4428,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786325400000},"marketStatusCode":5,"adr":0,"adjPreClose":36.46,"symbolType":"stock","openAndCloseTimeList":[[1786066200000,1786073400000],[1786078800000,1786086000000]],"highLimit":40.11,"lowLimit":32.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":451692766,"isCdr":false,"pbRate":8.51,"roa":"--","peRate":85.794941,"roe":"35.91%","epsLYR":-0.7478,"committee":0.38011,"marketValue":17160000000,"turnoverRate":0.0388,"status":0,"floatMarketCap":15925000000},"requestUrl":"/m/hq/s/300723","defaultTab":"news","newsList":[{"id":"2657652137","title":"股市必读:一品红(300723)8月5日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2657652137","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657652137?lang=zh_cn&edition=full","pubTime":"2026-08-06 01:19","pubTimestamp":1785950349,"startTime":"0","endTime":"0","summary":"截至2026年8月5日收盘,一品红报收于36.22元,上涨1.66%,换手率2.33%,成交量9.76万手,成交额3.51亿元。董秘最新回复投资者: 为何疼风药国内三期依然还在试验,那么久了,可否出来解释一下董秘: 尊敬的投资者您好,感谢您对公司的关注。2025年11月,公司在研的痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组。目前,正在进行关键性Ⅲ期临床试验,试验进展顺利。当日关注点交易信息汇总:8月5日主力资金净流入902.15万元,占总成交额2.57%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080600001386.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656531213","title":"一品红(300723)7月31日股东户数3.28万户,较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656531213","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656531213?lang=zh_cn&edition=full","pubTime":"2026-08-04 17:52","pubTimestamp":1785837142,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年7月31日公司股东户数为3.28万户,较6月30日减少248.0户,减幅为0.75%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至7月31日,化学制药行业平均股东户数为3.6万户。从股价来看,2026年6月30日至2026年7月31日,一品红区间跌幅为5.31%,在此期间股东户数减少248.0户,减幅为0.75%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400030080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535231","title":"一品红:2025年11月AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535231","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656535231?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:21","pubTimestamp":1785831674,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问:AR882三期临床已经到八月份了,去年十一月最后一组入组,到5月份应该已经结束了,请问进度如何,预计八月份能揭盲吗?一品红回复:尊敬的投资者您好,感谢您对公司的关注。2025年11月,公司在研的痛风创新药AR882(氘泊替诺雷)国内Ⅲ期临床试验完成全部患者入组。目前,正在进行关键性Ⅲ期临床试验,试验进展顺利。此外,药品研发具有周期长、投入高、风险大等特点,敬请广大投资者谨慎决策,注意投资风险。祝您投资愉快!本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400026659.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656535298","title":"一品红:截止至2026年7月31日,公司股东总户数32,828户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656535298","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656535298?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:21","pubTimestamp":1785831672,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)08月04日在投资者关系平台上答复投资者关心的问题。投资者提问:您好!请问截至7月底公司股东人数是多少,谢谢!一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年7月31日,公司股东总户数32,828户。祝您投资愉快。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400026654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656327573","title":"一品红(300723)7月31日股东户数3.28万户,较上期减少0.75%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656327573","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656327573?lang=zh_cn&edition=full","pubTime":"2026-08-03 17:43","pubTimestamp":1785750230,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年7月31日公司股东户数为3.28万户,较6月30日减少248.0户,减幅为0.75%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至7月31日,化学制药行业平均股东户数为3.6万户。从股价来看,2026年6月30日至2026年7月31日,一品红区间跌幅为5.31%,在此期间股东户数减少248.0户,减幅为0.75%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300024042.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656652321","title":"一品红:截止至2026年7月31日,公司股东总户数32,828户","url":"https://stock-news.laohu8.com/highlight/detail?id=2656652321","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656652321?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:12","pubTimestamp":1785744738,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)08月03日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘你好,股东人数?一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年7月31日,公司股东总户数32,828户。祝您投资愉快。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300019294.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656347567","title":"一品红最新公告:全资子公司拟中标348.17万元药品项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2656347567","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656347567?lang=zh_cn&edition=full","pubTime":"2026-08-03 11:49","pubTimestamp":1785728992,"startTime":"0","endTime":"0","summary":"一品红公告,公司全资子公司广州一品红制药有限公司与广州市联瑞制药有限公司参与第十二批全国药品集中采购,其中广州一品红制药有限公司的注射用硫酸艾沙康唑、广州市联瑞制药有限公司的培哚普利氨氯地平片(III)拟中标。根据公告,培哚普利氨氯地平片(III)2025年度预计实现销售收入348.17万元,占公司2025年度营业收入的0.37%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300010947.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653038637","title":"一品红(300723)披露2026年第二次临时股东会决议公告,7月24日股价下跌4.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653038637","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653038637?lang=zh_cn&edition=full","pubTime":"2026-07-24 22:10","pubTimestamp":1784902222,"startTime":"0","endTime":"0","summary":"截至2026年7月24日收盘,一品红报收于33.85元,较前一交易日下跌4.73%,最新总市值为152.9亿元。该股当日开盘35.38元,最高35.88元,最低33.7元,成交额达3.56亿元,换手率为2.46%。近日,一品红药业集团股份有限公司发布2026年第二次临时股东会决议公告。公告显示,公司于2026年7月24日召开2026年第二次临时股东会,会议由董事会召集,董事长李捍雄主持,采用现场与网络投票结合方式召开。出席会议股东共247人,代表有表决权股份总数的57.5383%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072400041711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772613","title":"一品红(300723)披露2025年股票期权激励计划部分股票期权注销完成公告,7月23日股价下跌1.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772613","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772613?lang=zh_cn&edition=full","pubTime":"2026-07-23 22:14","pubTimestamp":1784816061,"startTime":"0","endTime":"0","summary":"截至2026年7月23日收盘,一品红报收于35.53元,较前一交易日下跌1.31%,最新总市值为160.49亿元。近日,一品红药业集团股份有限公司披露《关于2025年股票期权激励计划部分股票期权注销完成的公告》。公告显示,2026年7月13日,公司召开第四届董事会第二十次会议,审议通过《关于注销2025年股票期权激励计划部分股票期权的议案》。因82名激励对象离职及218名激励对象个人绩效考核未达标,公司对其已获授但尚未行权的合计1,756,575份股票期权进行注销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300047960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653391717","title":"一品红(300723.SZ)子公司获得苯溴马隆片注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2653391717","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653391717?lang=zh_cn&edition=full","pubTime":"2026-07-23 15:49","pubTimestamp":1784792955,"startTime":"0","endTime":"0","summary":"智通财经APP讯,一品红(300723.SZ)发布公告,公司全资子公司广州一品红制药有限公司于近日收到国家药品监督管理局核准签发的关于苯溴马隆片的《药品注册证书》。此次获批的苯溴马隆片是以化学药品3类申报注册,视同通过一致性评价。该药品适应症为:原发性高尿酸血症,以及痛风性关节炎间歇期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一品红(300723.SZ)子公司获得苯溴马隆片注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652286228","title":"一品红(300723)披露2025年股票期权激励计划第一个行权期采用自主行权安排,7月17日股价下跌12.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652286228","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652286228?lang=zh_cn&edition=full","pubTime":"2026-07-17 22:06","pubTimestamp":1784297186,"startTime":"0","endTime":"0","summary":"截至2026年7月17日收盘,一品红报收于36.67元,较前一交易日下跌12.38%,最新总市值为165.64亿元。该股当日开盘40.77元,最高41.82元,最低35.84元,成交额达8.22亿元,换手率为5.04%。近日,一品红药业集团股份有限公司发布关于2025年股票期权激励计划第一个行权期采用自主行权的提示性公告。公司层面业绩考核中,2025年新获批创新药IND及获得药品注册批件数量达标,个人绩效考核结果已确定行权比例。行权后公司股权分布仍具备上市条件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700044503.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652406777","title":"7月17日一品红跌12.38%,新华鑫益灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652406777","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652406777?lang=zh_cn&edition=full","pubTime":"2026-07-17 16:55","pubTimestamp":1784278527,"startTime":"0","endTime":"0","summary":"证券之星消息,7月17日一品红跌12.38%,收盘报36.67元,换手率5.04%,成交量21.13万手,成交额8.22亿元。重仓一品红的公募基金请见下表:根据2026基金Q1季报公募基金重仓股数据,重仓该股的公募基金共3家,其中持有数量最多的公募基金为新华基金的新华鑫益灵活配置混合A。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030701.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651882624","title":"股市必读:一品红(300723)7月14日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2651882624","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651882624?lang=zh_cn&edition=full","pubTime":"2026-07-15 01:18","pubTimestamp":1784049491,"startTime":"0","endTime":"0","summary":"截至2026年7月14日收盘,一品红报收于40.71元,上涨3.43%,换手率4.71%,成交量19.73万手,成交额7.79亿元。董秘最新回复投资者: 董秘 您好 请问公司的AR882的三期临床研发数据大概什么时候出来?2025年11月,公司在研的痛风创新药AR882国内Ⅲ期临床试验完成全部患者入组。目前,正在进行关键性Ⅲ期临床试验,试验进展顺利。当日关注点交易信息汇总:7月14日主力资金净流出1566.39万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071500001766.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651173574","title":"一品红:2025年11月AR882国内Ⅲ期临床试验完成全部患者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2651173574","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651173574?lang=zh_cn&edition=full","pubTime":"2026-07-14 15:57","pubTimestamp":1784015829,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)07月14日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘 您好 请问公司的AR882的三期临床研发数据大概什么时候出来?一品红回复:尊敬的投资者您好,感谢您对公司的关注。2025年11月,公司在研的痛风创新药AR882(氘泊替诺雷)国内Ⅲ期临床试验完成全部患者入组。目前,正在进行关键性Ⅲ期临床试验,试验进展顺利。此外,药品研发具有周期长、投入高、风险大等特点,敬请广大投资者谨慎决策,注意投资风险。祝您投资愉快。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071400028408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651711706","title":"一品红(300723)披露2025年股票期权激励计划第一个行权期行权条件成就公告,7月13日股价下跌0.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2651711706","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651711706?lang=zh_cn&edition=full","pubTime":"2026-07-13 22:26","pubTimestamp":1783952778,"startTime":"0","endTime":"0","summary":"截至2026年7月13日收盘,一品红报收于39.36元,较前一交易日下跌0.98%,最新总市值为177.79亿元。一品红药业集团股份有限公司于2026年7月13日召开董事会,审议通过2025年股票期权激励计划第一个行权期行权条件成就的议案。公司层面业绩考核中,2025年新获批一个创新药IND且获得药品注册批件不少于10个,满足行权条件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071300040278.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649699103","title":"一品红(300723)披露召开2026年第二次临时股东大会通知,7月8日股价下跌2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649699103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649699103?lang=zh_cn&edition=full","pubTime":"2026-07-08 22:16","pubTimestamp":1783520179,"startTime":"0","endTime":"0","summary":"截至2026年7月8日收盘,一品红报收于37.69元,较前一交易日下跌2.36%,最新总市值为170.24亿元。近日,一品红药业集团股份有限公司发布《关于召开2026年第二次临时股东会的通知》。公告显示,公司将于2026年7月24日召开2026年第二次临时股东会,会议由董事会召集,现场会议时间为当日14:30,网络投票时间为同日上午9:15至下午15:00。股权登记日为2026年7月20日。登记时间为2026年7月23日,登记地点为公司证券部。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800042643.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649640435","title":"一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649640435","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649640435?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:37","pubTimestamp":1783330646,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年6月30日公司股东户数为3.31万户,较5月31日减少2934.0户,减幅为8.15%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.56万户。从股价来看,2026年5月31日至2026年6月30日,一品红区间跌幅为15.1%,在此期间股东户数减少2934.0户,减幅为8.15%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600024681.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649420644","title":"一品红:截止至2026年6月30日,公司股东总户数33,076户","url":"https://stock-news.laohu8.com/highlight/detail?id=2649420644","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649420644?lang=zh_cn&edition=full","pubTime":"2026-07-06 16:00","pubTimestamp":1783324838,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)07月06日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,股东人数一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年6月30日,公司股东总户数33,076户。祝您投资愉快本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070600019451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648265505","title":"一品红(300723)6月30日股东户数3.31万户,较上期减少8.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648265505","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648265505?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:38","pubTimestamp":1782985084,"startTime":"0","endTime":"0","summary":"证券之星消息,近日一品红披露,截至2026年6月30日公司股东户数为3.31万户,较5月31日减少2934.0户,减幅为8.15%。在化学制药行业个股中,一品红股东户数低于行业平均水平,截至6月30日,化学制药行业平均股东户数为3.53万户。从股价来看,2026年5月31日至2026年6月30日,一品红区间跌幅为15.1%,在此期间股东户数减少2934.0户,减幅为8.15%。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200029586.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300723"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648527770","title":"一品红:截止至2026年6月30日,公司股东总户数33,076户","url":"https://stock-news.laohu8.com/highlight/detail?id=2648527770","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648527770?lang=zh_cn&edition=full","pubTime":"2026-07-02 08:36","pubTimestamp":1782952570,"startTime":"0","endTime":"0","summary":"证券之星消息,一品红(300723)07月01日在投资者关系平台上答复投资者关心的问题。投资者提问:你好,股东人数一品红回复:尊敬的投资者您好,感谢您对公司的关注。截止至2026年6月30日,公司股东总户数33,076户。祝您投资愉快。本文数据来源于深圳证券交易所互动易,仅供参考不构成投资建议。责任编辑:陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200005992.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300723","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786090529922,"stockEarnings":[{"period":"1week","weight":0.0755},{"period":"1month","weight":-0.0554},{"period":"3month","weight":-0.1075},{"period":"6month","weight":0.0762},{"period":"1year","weight":-0.4882},{"period":"ytd","weight":0.0867}],"compareEarnings":[{"period":"1week","weight":0.0251},{"period":"1month","weight":-0.0225},{"period":"3month","weight":-0.0669},{"period":"6month","weight":-0.0406},{"period":"1year","weight":0.0733},{"period":"ytd","weight":-0.0173}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"一品红药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32828人(较上一季度减少0.75%)","perCapita":"12769股","listingDate":"2017-11-16","address":"广东省广州市黄埔区广州国际生物岛寰宇一路27号云润大厦17层","registeredCapital":"45169万元","survey":" 一品红药业集团股份有限公司的主营业务是药品研发、生产、销售。公司的主要产品是儿童药产品、慢病药产品。依托完善的创新研发体系,结合多年的市场经验,公司形成了覆盖面广、重点突出、阶梯化储备的产品结构,聚焦于特色儿童药及创新慢病药领域。截至本报告披露之日,公司(含全资及控股子公司)新增技术发明专利5项,目前,公司共有专利125项,其中国内专利114项,境外专利11项;共有商标477项,软件著作权45项。","listedPrice":17.05},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"一品红,300723,一品红股票,一品红股票老虎,一品红股票老虎国际,一品红行情,一品红股票行情,一品红股价,一品红股市,一品红股票价格,一品红股票交易,一品红股票购买,一品红股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"一品红(300723)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供一品红(300723)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}